Protection of the myocardium against postischemic reperfusion damage

Area of Science:

• Cardiology
• Cardiovascular Research
• Ischemic Heart Disease

Background:

• Reperfusion injury, a paradoxical deterioration of cardiac function upon restoring blood flow to ischemic myocardium, has been recognized for decades.
• Recent advancements in angiography and thrombolytic agents have enabled the demonstration of reperfusion in humans, highlighting its clinical significance.
• Reperfusion phenomena are now widely accepted as a critical factor in ischemic heart disease, with reperfusion damage potentially diminishing the efficacy of thrombolytic therapies.

Purpose of the Study:

• To review and discuss various agents investigated for their potential to mitigate reperfusion damage in ischemic myocardium.
• To explore the mechanisms of action of different classes of cardioprotective agents.
• To specifically examine the potential role of angiotensin converting enzyme inhibitors in reducing reperfusion injury.

Main Methods:

• Review of existing literature on reperfusion damage and cardioprotective agents.
• Discussion of various therapeutic agents and their proposed mechanisms of action.
• Focus on angiotensin converting enzyme inhibitors, analyzing their multifaceted effects relevant to reperfusion injury.

Main Results:

• Multiple classes of agents have been studied for their ability to reduce reperfusion damage.
• Angiotensin converting enzyme inhibitors exhibit promising characteristics due to their combined effects.
• These effects include modulation of norepinephrine levels, prostaglandin synthesis, and free radical scavenging.

Conclusions:

• Reperfusion damage is a significant clinical challenge in managing ischemic heart disease.
• Various pharmacological strategies are being explored to protect the myocardium during reperfusion.
• Angiotensin converting enzyme inhibitors represent a potential therapeutic avenue for reducing reperfusion injury due to their diverse beneficial actions.